Emerging Treatment Strategies in Pancreatic Cancer

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the main causes of cancer death in well-developed countries. Therapeutic advances in PDAC to date have been modest. Recent progress to understand the molecular landscape of the disease has opened new treatment opportunities for a small subset of patients, frequently those with KRAS wild-type disease. Novel treatment strategies in PDAC include, among others, the use of nanotechnology and metabolic reprogramming. In addition, new strategies are being investigated, which are designed to overcome the resistance to checkpoint inhibitors, targeting DNA repair pathways including mismatch repair, increasing antigen presentation through the use of vaccines, targeting various signaling pathways, and reprogramming the tumor microenvironment. Here, we review the landscape of PDAC treatment strategies and some of these new agents.

Manganese-based Prussian blue nanoparticles inhibit tumor proliferation and migration via the MAPK pathway in pancreatic cancer

“…A few advances have been made in disease diagnosis, perioperative management, and surgical skills over the past few decades, but these advances showed limited effects on the overall survival rate ( Zhao and Liu, 2020 ; Neoptolemos et al, 2021 ). Thus, novel therapeutic strategies are vital for PC treatment ( Trunk et al, 2021 ).…”